Quarterly report pursuant to Section 13 or 15(d)

Note 13 - Segment Information - Financial Information Relating to Reportable Segments (Details)

v3.19.3.a.u2
Note 13 - Segment Information - Financial Information Relating to Reportable Segments (Details) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2019
Dec. 31, 2018
Revenues, net $ 184,934 $ 174,510 $ 368,177 $ 337,480
Operating income 36,992 33,603 70,317 59,364
Costs recognized on sale of acquired inventory     0 (1,869)
Corporate general, selling, and administrative expenses (68,030) (63,603) (137,040) (130,655)
Operating Segments [Member]        
Operating income 61,847 57,897 122,285 115,047
Costs recognized on sale of acquired inventory 0 (935) 0 (1,869)
Amortization of acquisition related intangible assets (15,108) (15,002) (30,008) (29,278)
Acquisition related expenses 881 (348) (429) (2,973)
Stock based compensation (10,618) (6,861) (19,418) (18,426)
Operating Segments [Member] | Protein Sciences [Member]        
Revenues, net 141,517 135,462 282,512 261,852
Operating income 60,872 58,951 120,410 113,565
Operating Segments [Member] | Diagnostics and Genomics [Member]        
Revenues, net 43,846 39,263 86,397 76,010
Operating income 975 (1,054) 1,875 1,482
Intersegment Eliminations [Member]        
Revenues, net (429) (215) (732) (382)
Corporate, Non-Segment [Member]        
Corporate general, selling, and administrative expenses $ (12) $ (1,148) $ (2,113) $ (3,137)